title: [Therapy of organic brain syndrome with nicergoline given once a day].
abstract: In a double-blind, active-controlled study 30 patients with mild to moderate multiinfarct dementia diagnosed according to DSM III definition were treated by either 20 mg nicergoline or 4.5 mg co-dergocrine mesilate once daily during eight weeks. Therapeutic effects on symptoms of the organic brain syndrome were quantitatively measured by standardized psychological and psychometric methods evaluating cognitive and thymopsychic functions. Main criteria, which were tested by inferential analysis, were SCAG total score (Sandoz Clinical Assessment Geriatric Scale), SCAG overall impression and the AD Test (alphabetischer Durchstreichtest). Other results were assessed by descriptive statistics. Both treatments resulted in a statistically significant improvement in most of the tested functions. The effects of 4.5 mg co-dergocrine mesilate s.i.d. were in accordance with published results. Although differing slightly with respect to individual results 20 mg of nicergoline once daily showed the same efficacy on the whole.
authors.affiliation: Neurologische Abteilung, Universität Wien.
authors.forename: G
authors.initials: G
authors.lastname: Ladurner
authors.forename: P
authors.initials: P
authors.lastname: Erhart
authors.forename: C
authors.initials: C
authors.lastname: Erhart
authors.forename: V
authors.initials: V
authors.lastname: Scheiber
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001143:Arousal / Q000187:drug effects; D015161:Dementia, Multi-Infarct / Q000188:drug therapy* / Q000523:psychology; D004088:Dihydroergotoxine / Q000008:administration & dosage; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009530:Nicergoline / Q000008:administration & dosage* / Q000009:adverse effects; D014888:Wechsler Scales
chemical_list: D004088:Dihydroergotoxine; D009530:Nicergoline